CA2535902A1 - Uses of spatial configuration to modulate protein function - Google Patents
Uses of spatial configuration to modulate protein function Download PDFInfo
- Publication number
- CA2535902A1 CA2535902A1 CA002535902A CA2535902A CA2535902A1 CA 2535902 A1 CA2535902 A1 CA 2535902A1 CA 002535902 A CA002535902 A CA 002535902A CA 2535902 A CA2535902 A CA 2535902A CA 2535902 A1 CA2535902 A1 CA 2535902A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- function
- gene
- codon usage
- altered codon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004853 protein function Effects 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 94
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 31
- 230000014509 gene expression Effects 0.000 claims abstract description 19
- 108700010070 Codon Usage Proteins 0.000 claims abstract description 17
- 239000013598 vector Substances 0.000 claims abstract description 12
- 108020004705 Codon Proteins 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 7
- 108700005078 Synthetic Genes Proteins 0.000 claims description 6
- 238000004925 denaturation Methods 0.000 claims description 6
- 230000036425 denaturation Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 238000004153 renaturation Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 210000003000 inclusion body Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 102100036789 Protein TBATA Human genes 0.000 abstract description 2
- 101710118245 Protein TBATA Proteins 0.000 abstract description 2
- 108010050904 Interferons Proteins 0.000 description 18
- 102000014150 Interferons Human genes 0.000 description 18
- 101710142246 External core antigen Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000700721 Hepatitis B virus Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 229940047124 interferons Drugs 0.000 description 9
- 229940079322 interferon Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 229940090438 infergen Drugs 0.000 description 6
- 108010010648 interferon alfacon-1 Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 5
- 208000031636 Body Temperature Changes Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 3
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 238000002050 diffraction method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000015001 muscle soreness Diseases 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000169594 Paropsia Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101150092197 Stimate gene Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical compound O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 102220041913 rs587780812 Human genes 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940034337 stimate Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49878503P | 2003-08-28 | 2003-08-28 | |
| US49892303P | 2003-08-28 | 2003-08-28 | |
| US49844903P | 2003-08-28 | 2003-08-28 | |
| US60/498,785 | 2003-08-28 | ||
| US60/498,923 | 2003-08-28 | ||
| US60/498,449 | 2003-08-28 | ||
| IN279/MUM/2004 | 2004-03-05 | ||
| IN280/MUM/2004 | 2004-03-05 | ||
| IN280MU2004 | 2004-03-05 | ||
| IN279MU2004 | 2004-03-05 | ||
| PCT/US2004/028068 WO2005021777A2 (en) | 2003-08-28 | 2004-08-26 | Uses of spatial configuration to modulate protein function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2535902A1 true CA2535902A1 (en) | 2005-03-10 |
Family
ID=34280101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002535902A Abandoned CA2535902A1 (en) | 2003-08-28 | 2004-08-26 | Uses of spatial configuration to modulate protein function |
| CA2535982A Expired - Lifetime CA2535982C (en) | 2003-08-28 | 2004-08-26 | Uses of interferons with altered spatial structure |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2535982A Expired - Lifetime CA2535982C (en) | 2003-08-28 | 2004-08-26 | Uses of interferons with altered spatial structure |
Country Status (7)
| Country | Link |
|---|---|
| EP (3) | EP1663110B1 (enExample) |
| JP (4) | JP5663768B2 (enExample) |
| KR (2) | KR20060133949A (enExample) |
| AU (2) | AU2004279350B2 (enExample) |
| CA (2) | CA2535902A1 (enExample) |
| PL (2) | PL2325202T3 (enExample) |
| WO (2) | WO2005034853A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
| US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
| EP1663110B1 (en) * | 2003-08-28 | 2013-12-18 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
| WO2006076014A2 (en) * | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
| JP5209462B2 (ja) | 2005-03-09 | 2013-06-12 | ウェイ グアンウェン | コンセンサスインターフェロンの使用方法 |
| CN102101886A (zh) * | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
| TW201427681A (zh) * | 2013-01-07 | 2014-07-16 | Superlab Far East Ltd | 用空間構象改變的重組干擾素治療腫瘤的方法 |
| CN111363726A (zh) | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | 表达干扰素的溶瘤病毒及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US6579695B1 (en) * | 1995-10-13 | 2003-06-17 | President And Fellows Of Harvard College | Phosphopantetheinyl transferases and uses thereof |
| US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US20020043262A1 (en) * | 2000-08-22 | 2002-04-18 | Alan Langford | Spray device |
| EP2292652A2 (en) * | 2000-11-03 | 2011-03-09 | Pestka Biomedical Laboratories, Inc. | Interferons uses and compositions related thereto |
| CN1245215C (zh) * | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| EP1663110B1 (en) * | 2003-08-28 | 2013-12-18 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
-
2004
- 2004-08-26 EP EP04809634.1A patent/EP1663110B1/en not_active Expired - Lifetime
- 2004-08-26 EP EP10193126.9A patent/EP2325202B1/en not_active Expired - Lifetime
- 2004-08-26 WO PCT/US2004/028067 patent/WO2005034853A2/en not_active Ceased
- 2004-08-26 AU AU2004279350A patent/AU2004279350B2/en not_active Expired
- 2004-08-26 PL PL10193126T patent/PL2325202T3/pl unknown
- 2004-08-26 JP JP2006524916A patent/JP5663768B2/ja not_active Expired - Fee Related
- 2004-08-26 JP JP2006524917A patent/JP2007503812A/ja active Pending
- 2004-08-26 KR KR1020067003700A patent/KR20060133949A/ko not_active Ceased
- 2004-08-26 CA CA002535902A patent/CA2535902A1/en not_active Abandoned
- 2004-08-26 CA CA2535982A patent/CA2535982C/en not_active Expired - Lifetime
- 2004-08-26 AU AU2004269390A patent/AU2004269390A1/en not_active Abandoned
- 2004-08-26 EP EP04782529A patent/EP1670817A4/en not_active Ceased
- 2004-08-26 WO PCT/US2004/028068 patent/WO2005021777A2/en not_active Ceased
- 2004-08-26 PL PL04809634T patent/PL1663110T3/pl unknown
- 2004-08-26 KR KR1020067003699A patent/KR20060130009A/ko not_active Ceased
-
2011
- 2011-01-21 JP JP2011011325A patent/JP2011083292A/ja active Pending
-
2012
- 2012-05-28 JP JP2012121307A patent/JP5709800B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1158231A1 (en) | 2012-09-14 |
| PL2325202T3 (pl) | 2015-03-31 |
| JP5709800B2 (ja) | 2015-04-30 |
| EP1663110A2 (en) | 2006-06-07 |
| WO2005034853A3 (en) | 2006-04-27 |
| WO2005034853A2 (en) | 2005-04-21 |
| JP2007516214A (ja) | 2007-06-21 |
| AU2004269390A1 (en) | 2005-03-10 |
| EP1663110A4 (en) | 2008-07-16 |
| WO2005021777A3 (en) | 2005-05-12 |
| JP2012162567A (ja) | 2012-08-30 |
| KR20060130009A (ko) | 2006-12-18 |
| JP2007503812A (ja) | 2007-03-01 |
| CA2535982C (en) | 2016-11-29 |
| PL1663110T3 (pl) | 2014-07-31 |
| CA2535982A1 (en) | 2005-04-21 |
| EP1670817A4 (en) | 2008-07-16 |
| EP2325202B1 (en) | 2014-10-22 |
| AU2004279350B2 (en) | 2011-03-10 |
| EP1670817A2 (en) | 2006-06-21 |
| HK1091756A1 (en) | 2007-01-26 |
| AU2004279350A1 (en) | 2005-04-21 |
| EP2325202A1 (en) | 2011-05-25 |
| JP2011083292A (ja) | 2011-04-28 |
| WO2005021777A2 (en) | 2005-03-10 |
| JP5663768B2 (ja) | 2015-02-04 |
| EP1663110B1 (en) | 2013-12-18 |
| KR20060133949A (ko) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114805551B (zh) | 一种重组iii型胶原蛋白及其制备方法 | |
| US5591601A (en) | DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system | |
| Unterreitmeier et al. | Phenylalanine promotes interaction of transmembrane domains via GxxxG motifs | |
| TWI720268B (zh) | 製備電轉感受態酵母細胞的方法以及使用所述細胞的方法 | |
| JPS59501572A (ja) | クルイベロミセス属酵母およびその製造法 | |
| JP2014000082A (ja) | シンターゼ | |
| JPWO1997018318A1 (ja) | レトロウイルスによる標的細胞への遺伝子導入方法 | |
| CA2535902A1 (en) | Uses of spatial configuration to modulate protein function | |
| Zeng et al. | Molecular basis of CONSTANS oligomerization in FLOWERING LOCUS T activation | |
| CN120659875A (zh) | 一种转座酶、转座子、转座子系统及其应用 | |
| CN114621333B (zh) | 甜瓜苦味物质葫芦素b的转运蛋白及其应用 | |
| CN114107253B (zh) | 一种利用工程细胞进行基因编辑的系统及方法 | |
| JP3355049B2 (ja) | 組換え人ミオグロビンの製造方法 | |
| CA1297434C (en) | Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same | |
| JPH08502653A (ja) | 形質転換内皮細胞 | |
| KR102005685B1 (ko) | 한국 분리주 메르스 코로나 바이러스 유래의 형광 단백질 발현 메르스 코로나 바이러스 재조합 벡터 및 이의 제조방법 | |
| CN118852413A (zh) | 一种重组ⅱ型胶原蛋白及其在凝血和组织再生中的应用 | |
| AU606049B2 (en) | Inducible heat shock and amplification system | |
| CA2609473A1 (en) | A recombinant method for production of an erythropoiesis stimulating protein | |
| US20130281667A1 (en) | Uses of spatial configuration to modulate protein function | |
| RU2646111C2 (ru) | Экспрессионный плазмидный лентивирусный вектор для гетерологической экспрессии рекомбинантного человеческого белка cd44 | |
| CN106434745A (zh) | 一种利用烟草高效表达il‑37各亚型成熟蛋白的方法 | |
| CN117143223B (zh) | 一种生物合成人体结构性材料的制备方法 | |
| CN120290557A (zh) | 一种通用的且无“scar”的RNA环化方法 | |
| CN120665163A (zh) | 大豆疫霉fha1蛋白及其在筛选ppi抑制剂中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20121231 |